GLP1R and heart failure: Conversely, the phase 2 Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) study demonstrated that liraglutide treatment (uptitrated to 1.8 mg once daily) over 180 days in subjects with severe heart failure (LVEF ≤40%) resulted in a numerical increase in rates of death or rehospitalization for heart failure (P = 0.14) (Margulies et al., 2016).